To assess the outcome of unrelated umbilical cord blood transplantation (UCBT), 141 children with AML who underwent UCBT (39 in first CR (CR1), 33 in CR2, 4 in CR3 and 65 at more advanced stages (not in CR)) were analyzed in a retrospective multicenter study in Japan. Short-term MTX was used for prophylaxis of acute GVHD in 80 cases (57%). The cumulative incidences of neutrophil recovery, platelet recovery and acute GVHD (grades 2-4) were 78.7, 62.4 and 40.1%, respectively, and the 100-day transplantation-related mortality (TRM) was 10.8%. Multivariate analysis showed that an infused CD34 þ cell dose of 1.35 Â 10 5 cells per kg or more was associated with favorable neutrophil and platelet recovery, and that short-term MTX was associated with a lower 100-day TRM. The 6-year relapse rate was 38.8% and was associated with disease status. Six-year overall survival was 45.8% (70.4 ± 8.3% in CR1, 59.3 ± 11.3% in CR2, 75.5 ± 21% in CR3 and 20.6 ± 6.2% for children with non-CR). We conclude that the results of UCBT are particularly promising for children with a karyotype suggesting a poor prognosis, and for those who receive transplants in CR2 and CR3 after an early relapse.
Introduction
With currently available treatment, 80-90% of children with AML achieve CR, but 30-40% of these patients subsequently suffer recurrence, reducing the long-term survival rate to only about 50%. [1] [2] [3] [4] After recurrence, the likelihood of survival is poor, being 21-33% according to recent reports. [5] [6] [7] [8] BMT from an HLA-matched sibling or unrelated donor has a major role in the treatment of children with high-risk or relapsed AML. [9] [10] [11] However, although there are currently more than 250 000 donors registered in the Japan Marrow Donor Registries Program, a substantial proportion of children who lack a sibling donor will never undergo BMT from an HLA-matched unrelated donor either because such a donor cannot be found or because the time required to identify a donor is too long. Moreover, for children who undergo unrelated BMT, the increased HLA disparity adversely affects survival because of the high risk of GVHD and opportunistic infections.
Hematopoietic stem cells from an unrelated cord blood (UCB) transplant can restore hematopoiesis and immune function after a myeloablative conditioning regimen, even if the graft is not perfectly HLA identical to the recipient. [12] [13] [14] [15] This important medical advance led to the establishment of large cord blood (CB) banks that made possible the use of UCB to provide transplants for patients lacking a conventional related or unrelated BM (UBM) donor. In addition, when compared with the availability of UBM grafts, UCB offers the advantage of significantly faster availability of banked cryopreserved UCB units. A previous comparative study of children receiving UCB or UBM transplants for acute leukemia revealed that the relapse rate did not increase after umbilical cord blood transplantation (UCBT). 16 However, it was not possible to report specific data for children with AML at different disease stages because of the relatively small number of patients in each subgroup. [17] [18] [19] [20] [21] Using data from the Japan Cord Blood Bank Network (JCBBN) registry, we are now able to report outcomes and their association with patient-, disease-and transplant-related factors for 141 children who underwent UCBT as an initial hematopoietic stem cell transplantation (HSCT) procedure for AML.
Patients, materials and methods

Patient selection criteria
All children reported to the JCBBN registry as having undergone UCBT for AML were included in this study, with the exception of those with either Down's syndrome or Fanconi anemia. A total of 141 children aged 15 years or younger who received transplants from August 1997 through March 2006 in 60 centers in Japan (see Appendix) were analyzed. Patients with AML (with high-risk karyotypes, secondary AML, megakaryoblastic leukemia or absence of remission after the first course of chemotherapy) in first CR (CR1), second CR (CR2), third CR (CR3) and no CR (non-CR) were candidates for UCBT. Approval for this study was obtained from the JCBBN institutional review board. Informed consent was obtained in accordance with the Declaration of Helsinki Principles.
Patient characteristics
The characteristics of the 141 children who received UCBT as their initial HSCT procedure are listed in Table 1 . Four of them were considered to have secondary AML on the basis of a history of exposure to chemotherapy or radiotherapy, a history of myelodysplasia or Blackfan Diamond anemia. Abnormal karyotypes were classified into the favorable-risk group if t(8; 21), t(15; 17) or inv(16) was detected. In patients lacking these favorable karyotypes, the presence of monosomy 7, 11q23 abnormalities other than t(9;11), monosomy 5, del(5q), abnormal 3q, t(6; 9) or a complex karyotype involving the presence of five or more abnormalities were defined as a poor-risk group. The remaining abnormalities were classified as an intermediaterisk group. At the time of UCBT, 39 children were in their CR1; 14 patients with a poor-risk karyotype and 21 of 25 patients with a poor response to the first course of chemotherapy without a poor-risk karyotype were included, 32 were in their CR2, 4 were in their third or subsequent CR and 65 were non-CR.
Umbilical cord blood characteristics and the transplantation procedure Eligibility. The clinical protocols for UCBT were approved by the institutional review board of each participating institution. Patients were eligible for enrollment if their disease was stable but had no HLA-identical related or unrelated donor; or if their disease was unstable with no related donors or an HLA-matched UBM donor could not be identified within 6-8 weeks. The disease status of those with hematological malignancies was categorized according to the criteria specified in the International Bone Marrow Registry. 22 Donor registries and selection of grafts. Searches for unrelated CB donors were processed through the JCBBN, through which over 28 000 CB units were made available in August 2006. A preliminary search of umbilical CB banks was performed by using the patient's HLA phenotype, as determined by serologic typing for class I HLA-A and HLA-B antigens and low-resolution DNA typing for class II HLA-DRB1 alleles. High-resolution DNA typing of class I and/or II HLA alleles was performed on physician's request. Preferred UCB units were those matched at four or more of six HLA antigens and that contained a minimum count of 2 Â 10 7 nucleated cells per kg of the recipient's body weight before freezing. Units of UCB were not depleted of T lymphocytes. Use of HLA-A and -B serology and low-resolution allelic DRB1 typing showed that most of the children had either one (65%) or two (13%) disparities with their graft ( Table 2 ). The CD34 þ cell counts were analyzed by the two most commonly used CD34 þ cell quantification methods (ISHAGE protocol and ProCount; Becton Dickinson, Franklin Lakes, NJ, USA) 23 at 11 regional CB banks.
Preparative regimen and prophylaxis against GVHD. The conditioning regimen and acute GVHD prophylaxis varied according to the policy of each center, type of disease, prior treatment and disease status at the time of UCBT. The patients or their parents gave consent for UCBT after being informed of the potential risks and benefits of the procedure. The GVHD prophylaxis is summarized in Table 2 . Standard short-term MTX prophylaxis for GVHD was given at a dose of 10-5 mg/m 2 on day 1 and 7.5-10 mg/m 2 on days 3, 6 and 11. Supportive therapy differed among the transplant centers. Protocols for intensive myeloablative therapy and the use of UCBs for transplantation were reviewed and approved by the institutional review boards at the transplantation centers.
Statistical methods
For this analysis, 1 July 2007 was used as the reference date (that is, the day on which all centers locked data on patient outcomes). The median duration of follow-up was 31 months (range, 3-92 months). The outcome end points were neutrophil recovery, platelet recovery, GVHD, relapse, TRM, OS and disease-free survival (DFS). Categorical data in cross-tabulation tables were compared by using the Fisher's exact test. Neutrophil recovery was defined by an ANC of at least 0.5 Â 10 9 per liter for 3 consecutive days, the first of which was used as the recovery day. Platelet recovery was defined by a nontransfused platelet count of at least 20 Â 10 9 per liter for 7 consecutive days. Death occurring before day 90 or 180 was considered as a competing risk for neutrophil or platelet recovery, respectively. Graft failure rates for neutrophils or platelets were calculated for patients surviving without relapse or autologous infusion (competing events) for more than 90 or 180 days, respectively. Acute and chronic GVHD were diagnosed and graded at each center according to standard criteria. 24, 25 Relapse was defined on the basis of morphological evidence of leukemia in the BM or other extramedullary organs. TRM was defined as all causes of nonleukemic death occurring after transplantation. OS was the time between transplantation and death due to any cause. DFS was defined as the time interval from UCBT to the first event, either relapse or death, during CR. These outcomes were all right censored. For OS and DFS, the Kaplan-Meier method provided an estimate of the incidences over time, whereas the Cox models were used to evaluate the joint influence of patient-, disease-and transplant-related variables on the outcome. However, the other end points shared a competing risk setting, if patients developed events that avoided the occurrence of the event of interest. For example, after death or a relapse before engraftment, no recovery or GVHD could occur. Therefore these end points (neutrophil and platelet recovery, acute and chronic GVHD, relapse and TRM) were analyzed by using cumulative incidence curves for estimating the incidence over time, and Fine and Gray models were used to assess prognostic factors. 26, 27 For all models, we first fitted univariate models that contained each of the variables one at a time. Second, the values of all variables with a P-value below 0.1 by the likelihood ratio test were included in a multivariate model. Cause-specific hazard ratios were estimated with 95% confidence intervals. All statistical analyses were performed with STATA software version 8.0 (Stata Inc., College Station, TX, USA).
Results
Neutrophil and platelet recoveries
The cumulative incidence of neutrophil recovery at day 90 was 78.7±3.4%. During the first 90 days after transplantation, competing risk for neutrophil recovery was death (n ¼ 11). The graft failure rate for neutrophil recovery was 21% (30 of 141 patients). For those patients who recovered, the median time to achieve an ANC equal to or more than 0.5 Â 10 9 per liter was 28 days (range, 13-90 days). In univariate analysis, factors associated with neutrophil recovery were as follows- (1) status of disease at transplantation: cumulative incidence of neutrophil recovery at day 90; the neutrophil recovery rate was 82.9 ± 4.3% for children who received transplants in remission (CR1, CR2 and CR3) vs 73.8±5.5% for those with non-CR; P ¼ 0.04; (2) the CD34 þ cell dose: the cumulative incidence of neutrophil recovery rate was 89.7±3.9% when 1.35 Â 10 5 per kg or more CD34 þ cells were infused vs 60.9±7.2% when less than 1.35 Â 10 5 per kg CD34 þ cells were infused; Po0.0001; Figure 1a . There was a trend toward neutrophil recovery when prophylactic use of G-CSF was present (79.4 ± 3.9 vs 76.5 ± 7.3% when hematopoietic growth factor was not used, P ¼ 0.092). No other factors affecting neutrophil recovery had a significant influence. In multivariate analysis, the factor associated with an improved neutrophil recovery was infusion of CD34 þ cells at a dose of 1.35 Â 10 5 per kg or more (Table 3 ). The day 180 cumulative incidence of platelet recovery was 62.4 ± 4.9%. During the first 180 days after transplan- (13) tation, the competing risk for platelet recovery was death (n ¼ 34). The graft failure rate was 37.8% for platelet recovery (53 of 141 patients). For patients who recovered, the median time to achieve platelet recovery was 56 days (range, 14-180 days). In univariate analysis, the factors associated with platelet recovery were as follows- (1) Figure 1b ; (3) short-term MTX for GVHD prophylaxis: the cumulative incidence of platelet recovery rate was 70.0 ± 5.1 vs 52.5 ± 6.4% when MTX was not used; P ¼ 0.016. The use of prophylactic hematopoietic growth factor and period of transplantation were not significantly associated with the speed or incidence of platelet recovery. In multivariate analysis, the factors associated with an improved platelet recovery were CR at transplantation (CR1, CR2 and CR3) and CD34 þ cell dose (infusion of 1.35 Â 10 5 per kg or more CD34 þ cells) ( Table 3) .
Acute and chronic GVHD Acute GVHD (grade II or more) was observed in 54 patients (44 in grade II, 8 in grade III and 2 in grade IV). The 100-day cumulative incidence of acute GVHD was 40.1. No patient-, disease-, or transplant-related factors that could be associated with the incidence of acute GVHD were found. Notably, the number of HLA disparities of GVH direction between CB and recipient was not significantly associated with grades II-IV acute GVHD. Two years after UCBT, the cumulative incidence of chronic GVHD was 14.7 ± 3.5%. Of the 123 patients at risk, 15 presented signs of chronic GVHD (10 with limited and 5 with extensive signs).
Early transplant-related mortality During the first 100 days after UCBT, 15 patients succumbed to 29 episodes of transplantation-related complications (11 episodes of infection, 6 episodes of bleeding and 13 other events) and competing risks for TRM at day 100 (100-day TRM) was relapse (n ¼ 21). The main cause of CBT-related death was interstitial pneumonia. The cumulative incidence of 100-day TRM was 10.8 ± 2.6%. In univariate analysis, the following factors were associated with an increased risk of death-(1) the use of short-term MTX for GVHD prophylaxis: the death rate was 19.9±5.1% when MTX was not used vs 3.8±2.2% when used, P ¼ 0.0026, Figure 2a ; (2) date before December 1999: the death rate was 26.9 ± 8.7 vs 7.0 ± 2.4%, P ¼ 0.0031, Cord blood transplantation for children with AML K Isoyama et al Figure 2b . Fisher's exact test showed that proportional deviations between the use of short-term MTX for GVHD prophylaxis and the time of UCBT were significant (19 of 26 patients were not treated with short-term MTX in or before 1999, whereas 42 of 115 patients were not treated with MTX after 2000, P ¼ 0.0009). Multivariate analysis showed that the only factor associated with an increased early TRM was the non-use of short-term MTX as part of the GVHD prophylaxis (Table 3 ). There was marginal significant difference between a trend toward an increased risk of death when patients received infusion of CD34 þ cells at doses below 1.35 Â 10 5 per kg (13.1 vs 5.2% for those receiving more than 1.35 Â 10 5 per kg, P ¼ 0.051).
Relapse incidence
Hematological relapses occurred in 46 patients after UCBT, and 27 patients succumbed with experiencing disease recurrence. The 6-year cumulative relapse incidence (RI) was 41.3±4.8%. In univariate analysis, the following two factors were associated with an increased risk of relapse: age under 4 years (51.0 ± 6.2 vs 26.5 ± 7.0%, P ¼ 0.0027); non-CR at transplantation (68.2±7.3% for more advanced disease status vs 23.5 ± 5.4% for those in remission (CR1, CR2 and CR3, Po0.00001; Figure 3a ). More precisely, the 6-year cumulative RI was 15.2±6.3% for patients who received transplants in CR1, 33.7±9.3% for those in CR2 and 68.2 ± 7.5% for those with non-CR at the time of UCBT. The RI after UCBT in children presenting poor-risk cytogenetic abnormalities was 25.4±9% compared with 47.1 ± 7% in others (P ¼ 0.12). The absence of previous acute GVHD (grades II-IV) was not associated with an increased RI (P ¼ 0.62). The patients were divided into two groups for each of two separate categories: a poor-risk group and a favorable-risk and an intermediate-risk group, according to karyotype; and groups within and beyond the median period (330 days) of initial remission. However, no statistically significant differences were noted among these groups. In multivariate analysis, the two factors associated with an increased relapse rate were lack of CR at UCBT and age under 4 years at UCBT.
Disease-free survival, overall survival and causes of death A total of 64 patients succumbed; causes of death were disease relapse in 27, transplantation-related events in 29 (Table 4) , unknown etiology in 4 and other reasons in 6. The estimated 6-year OS and DFS were 46.1 ± 5.0 and 39.3 ± 4.7%, respectively. In univariate analysis, the most significant factor was disease status at the time of UCBT. The 6-year DFS was 53.8 ± 6.9% for children who received transplants during remission (CR, CR2 and CR3), in contrast to 0% for those with non-CR (Po0.0001; Figure 3b ). The 6-year DFS was 67.7 ± 7.8% for children who received transplants during the CR1, 49.6 ± 11.3% for those in the CR2, 75±21% for those in CR3 or beyond and 0% for non-CR at the time of UCBT. No other factors affecting DFS had a statistically significant influence. More precisely, the 6-year DFS were 53.3 ± 8.9% for children with a poor prognostic karyotypes, 41.6±7.6% for those with intermediate karyotypes and 39.6 ± 9.0% for those with favorable karyotypes (P ¼ 0.67), 39.7 ± 5.7% for children received non-TBI-based conditioning regimen and 0% for those with TBI regimen (P ¼ 0.66). The 6-year DFS was not significantly affected by the frequency of exposure to HLA mismatches; 38.4±9.3% for children who received transplants with HLA-identical donor, 19.6 ± 14.2% for those with HLA 1 mismatch, and 43.3±13.6% for those with HLA 2 mismatch (P ¼ 0.93).
In multivariate analysis, the only factor associated with DFS was CR at UCBT ( Table 3 ). The 6-year OS was 65.6 ± 6.8% for children who received transplants during remission (CR, CR2 and CR3) vs 20.6 ± 6.2% for those without CR (Po0.0001). More precisely, the 6-year OS was 70.4 ± 8.3% for those who received transplants in the first CR, 59.3±11.3% for those in the second CR, 75 ± 21% for those in CR3 and 20.6 ± 6.2% for those who were non-CR at the time of UCBT (Figure 3c ). There was marginal significant difference between prophylactic use of MTX for GVHD and no use of MTX for GVHD (51.7 ± 6.7 vs 39.7 ± 7.3%, P ¼ 0.074). No other factors affecting OS had a statistically significant influence. In multivariate analysis, the only factor associated with OS was CR at UCBT (Table 3 ). Log rank: P<0.0001 Log rank: P<0.0001 Figure 2 The cumulative incidence of 100-day transplantation-related mortality (100-day TRM). Cumulative incidence of 100-day TRM according to use of MTX for prophylaxis for GVHD (a) and 100-day TRM according to the date of unrelated cord blood transplantations (b).
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Discussion
To the best of our knowledge, this is the first 6-year retrospective registry-based analysis to have been specifically designed to clarify the results of UCBT for childhood AML in Japan. As expected, and described previously, 19 it was found that outcome was associated with disease status at the time of transplantation. UCBT applied during remission for pediatric AML is important, and gives a better outcome when conducted in children with active leukemia. Only four patients in the present series were in CR3. Future studies using a larger number of patients are therefore warranted.
Recently, in cases of pediatric AML during remission, there has been a tendency to base the indication for HSCT on the risk classification at the time of diagnosis. 28 In the Medical Research Council 12 study, the estimated probability of 5-year survival from CR in 51 high-risk patients (including 31 with BMT from sibling donors at first CR) was 47%, and DFS 41%. 1 In the BFM 1993 study, the 5-year event-free survival of 310 children with AML treated with HSCT was 50%, whereas their OS was 54%. 2 In our study, the DFS and OS in 39 patients with AML treated with UCBT from unrelated donors (conducted during the first remission) were 67.7 ± 7.8 and 70.4 ± 8.3%, respectively. Our results are therefore comparable to those of other studies. For some reasons, unclear at this time, survival rate in our study is higher than previously published.
The prognosis of AML after recurrence is poor, with a survival rate ranging from 21 to 33%, according to recent Cord blood transplantation for children with AML K Isoyama et al reports. [5] [6] [7] [8] The present study indicated that the DFS and OS among 33 children with AML treated with UCBT during the second CR were 49.6 and 59.3%, respectively. However, several recent reports have indicated that CR1412 months is critical to salvage and improve OS rates in children with AML without the benefit of SCT; 5 the OS is around 50% in this group of patients. Further investigation is needed because our patients who suffered relapses comprised a heterogeneous group: among the 33 patients in our series who were in CR2, 24 had CR1 412 months and were still responsive to chemotherapy, and 9 suffered recurrence less than 12 months after initial diagnosis. The DFS and OS of these nine patients were 45.5±18.8 and 72.9±16.5%, respectively. This indicates that UCBT at CR2 may achieve results similar to those reported by others, even in AML patients with early recurrence. The results of UCBT were particularly promising for children with high-risk AML at CR1, and the procedure also holds promise for those who are in CR2 and CR3 after early relapse. The outcome of UCBT for non-CR children with AML was poor in our study. For those patients, a haploidentical HSCT may be another stem cell source. However in non-CR children with AML, convincing studies are missing comparing stem cell sources, conditioning regimen or graft manipulation. 29 Therefore, no final judgment on these issues is possible to date. The karyotype of malignant cells is known to be one of the most relevant predictors of treatment outcome in childhood AML. 28 In our study, 24% of the patients for whom cytogenetic analysis was successful were classified into the poor-risk cytogenetic category. Interestingly, however, the 6-year DFS and the incidence of relapse among these children with a poor-risk karyotype were not significantly different from those in children with a favorable-risk karyotype (53.3 ± 8.9 vs 30.6 ± 9.9%, P ¼ 0.52 and 30.7 ± 9.2 vs 39.1 ± 10.0%, P ¼ 0.94, respectively).
In the present study, the 100-day cumulative TRM was 10.8%. This incidence is lower than those reported in other series of studies on children receiving UCBT. 17, 19, 30, 31 Apparently, TRM constitutes a principal obstacle discouraging wider application of UCBT in children with high-risk AML, as it does to CBT in many other diseases. When short-term MTX was used for GVHD prophylaxis, the 100-day TRM was reduced to 3.8%. Short-term MTX has been demonstrated to be effective for GVHD prophylaxis when combined with a calcineurin inhibitor in patients receiving BM or PBSC transplantation. [32] [33] [34] Recently, it has been demonstrated that short-term MTX was associated with a lower rate of post transplantation immune reactions without compromising engraftment, resulting in better OS in adult UCBT recipients. 34 It has been suggested that the favorable impact of short-term MTX is due to attenuation of organ damage resulting from post-UCBT immune reactions and the avoidance of corticosteroids to reduce the risk of infectious complications. However, the effectiveness of short-term MTX in UCBT for children with AML remains unclear. In UCBT with short-term MTX for GVHD prophylaxis, the 100-day TRM was significantly reduced. This suggests that shortterm MTX, when applied to pediatric AML as a singledisease entity, also suppresses any early immune reaction, as is the case in adults. It is likely that the use of short-term MTX ultimately affects the incidence of TRM. This is the first report describing the efficacy of short-term MTX in association with UCBT for treatment of AML in children. Univariate analysis showed that the incidence of 100-day TRM was 23.1% in transplantations carried out before December 1999 (n ¼ 26), and 6.1% thereafter (n ¼ 115). In addition, when the dose of infused CD34 þ cells exceeded the median (1.35 Â 10 5 per kg), the 100-day TRM incidence tended to decrease (to 5.2%), 35 showing that the dose of infused CD34
þ cells was a more potent indicator of prognosis than that of nucleated cells. In that study, there was a threshold of 1.7 Â 10 5 CD34 þ cells per kg, and the authors suggested that UCB units containing less than this dose of CD34 þ cells should be considered inadequate for routine use because of the very high TRM risk. 35 Our present study is the first reported study to have produced similar results for a single-disease entity. These issues are crucial in the choice of UCBT for any given patient, but would be more efficiently addressed in large registry studies than in a disease-specific study like ours. The rarity of use of short-term MTX for prevention of GVHD before 1999 may explain the high incidence of TRM at that time. Our findings indicate that to reduce the incidence of TRM shortly after UCBT for pediatric AML, it is essential to use a sufficient dose of CD34 þ cells to hasten the recovery of the neutrophil population, and to administer simultaneously short-term MTX to prevent early immune reactions.
The incidences of relapse are comparable to those reported after BMT from unrelated HLA-matched donors. [9] [10] [11] In the Seattle experience of 161 patients with AML who received unmanipulated BM transplants from unrelated donors, the cumulative incidences of relapse were 19% in CR1, 23% in CR2, 25% in subsequent CR, 44% during relapse and 63% during primary induction failure. 10 Among the 91 patients with AML who received CBT from unrelated donors in the analysis conducted by the Eurocord Group 19 , the cumulative incidences of relapse were 10±7% in CR1, 23±7% in CR2, 1 of 4 patients in subsequent CR and 61 ± 11% during primary induction failure. The present study included an evaluation of the association of well-identified prognostic factors of childhood AML, such as the karyotype of the malignant cells, 28 and the duration of the first CR in children who received transplants during their second CR. 36 Our results suggest that these two prognostic factors, identified in patients with AML undergoing concomitant chemotherapy or standard allogeneic BMT, may not have the same predictive value in the context of unrelated UCBT. This potent antileukemic effect in poor-risk AML supports the hypothesis of an adequate GVL effect after UCBT. Our results revealed that transplantation during a period other than that of remission constitutes the sole risk factor for relapse.
The results of UCBT were particularly promising for children with a karyotype suggesting a poor prognosis, and in those who received transplants in CR2 and CR3 after an early relapse. In the absence of a randomized trial, we cannot definitively state the relative efficacy of BM and CB grafts, but the data support the use of CB grafts in children with acute leukemia.
